This document provides an overview of COVID-19 and summarizes key information about the virus. It discusses that COVID-19 is caused by a novel coronavirus called SARS-CoV-2. The document covers epidemiology of the virus, symptoms, at-risk groups, testing guidelines, treatment approaches which are currently symptomatic, and prevention methods like hand washing and social distancing. It also summarizes guidance on specimen collection, laboratory testing, and current investigational drugs and vaccines being explored to tackle the pandemic.
A real-time polymerase chain reaction (real-time PCR), also known as quantitative polymerase chain reaction (qPCR), is a laboratory technique of molecular biology based on the polymerase chain reaction (PCR). It monitors the amplification of a targeted DNA molecule during the PCR (i.e., in real time), not at its end, as in conventional PCR.
The reverse transcription - polymerase chain reaction (RT-PCR) is a sensitive technique for the quantification of steady-state mRNA levels, particularly in samples with limited quantities of extracted RNA, or for analysis of low level transcripts. The procedure amplifies defined mRNA transcripts by taking advantage of retroviral enzymes with reverse transcriptase (RT) activity, coupled to PCR.
Covid19. In this presentation we covered What is COVID-19 virus?, CASE DEFINITION, Website, High Risk Population, TYPES OF CASES, COMMON SYMPTOMS, Laboratory diagnosis, General guidelines for sampling, FREQUENCY OF TESTING, PREVENTION OF COVID19. SYMPTOMATIC TREATMENT, Vaccine available in market.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)ChiagozieHenry1
This presentation gives a detailed summary of what we know so far about severe acute respiratory syndrome 2 coronavirus (SARS- CoV-2) previously known as novel coronavirus.
Transmission, signs and symptoms, treatment, prevention and control of coronavirus disease (CoVID-19) are also highlighted.
A real-time polymerase chain reaction (real-time PCR), also known as quantitative polymerase chain reaction (qPCR), is a laboratory technique of molecular biology based on the polymerase chain reaction (PCR). It monitors the amplification of a targeted DNA molecule during the PCR (i.e., in real time), not at its end, as in conventional PCR.
The reverse transcription - polymerase chain reaction (RT-PCR) is a sensitive technique for the quantification of steady-state mRNA levels, particularly in samples with limited quantities of extracted RNA, or for analysis of low level transcripts. The procedure amplifies defined mRNA transcripts by taking advantage of retroviral enzymes with reverse transcriptase (RT) activity, coupled to PCR.
Covid19. In this presentation we covered What is COVID-19 virus?, CASE DEFINITION, Website, High Risk Population, TYPES OF CASES, COMMON SYMPTOMS, Laboratory diagnosis, General guidelines for sampling, FREQUENCY OF TESTING, PREVENTION OF COVID19. SYMPTOMATIC TREATMENT, Vaccine available in market.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)ChiagozieHenry1
This presentation gives a detailed summary of what we know so far about severe acute respiratory syndrome 2 coronavirus (SARS- CoV-2) previously known as novel coronavirus.
Transmission, signs and symptoms, treatment, prevention and control of coronavirus disease (CoVID-19) are also highlighted.
covid-19 disease or novel corona virus disease or sars-cov 2 information includes all about virology,patho physiology, taxonomy of virus, taxonomy of intermediary host pangolin,and preventive measures needed to be followed by public etc, in a most possible concised manner illustrated in this presentation.
Corona virus disease-2019 (Covid-19 outbreak) epidemiology prevention and con...Arun Singh
This PPT is created and updated on 14 February 2020 and it is about the epidemiology of Corona Virus Disease-19, Its preventive measures were also given, useful for department of Community Medicine
There's a lot of information circulating about COVID-19, the disease caused by the new coronavirus, so it’s important to know what’s true and what’s not.
COVID-19
ALSO USEFUL FOR NEET, CET, JIPMER, AIIMS, OTHER MEDICAL ENTRANCES.
WATCH THE FULL VIDEO ON YOUTUBE:
https://youtu.be/1NQQvLH3xo0
SUBSCRIBE ON YOUTUBE !!
SUB-TOPICS INCLUDED ARE:
Introduction
Structure of SARS-CoV-2
Types of SARS-CoV-2
Transmission of SARS-CoV-2
Viability of the virus
Symptoms of COVID- 19
Diagnosis
Treatment
FOLLOW ON INSTAGRAM:
@stud_e_
https://www.instagram.com/stud_e_/
COVID-19 I Coronavirus Disease I Harshit JadavHarshit Jadav
This presentation highlights all the basic information regarding the current pandemic COVID-19.
This presentation includes an introduction, recent stats, the structure of coronavirus, pathogenesis of coronavirus, diagnosis, treatment and preventive measures of COVID-19
Coronaviruses are a large family of respiratory viruses that includes COVID-19MOHAhmed18
Coronaviruses are a large family of respiratory viruses that includes COVID-19, Middle East Respiratory Syndrome (MERS), and Severe Acute Respiratory Syndrome (SARS). Coronaviruses cause diseases in animals and humans. They often circulate among camels, cats, and bats, and can sometimes evolve and infect people.
Covid-19 is an infectious disease caused by SARS-CoV-2. mechsnism, pathogenesis and causes, transmission,symptoms and therapeutic strategies
Published by karuna raghuwanshi,M.pharma II semester (pharmaceutics),Pharmacy department.
covid-19 disease or novel corona virus disease or sars-cov 2 information includes all about virology,patho physiology, taxonomy of virus, taxonomy of intermediary host pangolin,and preventive measures needed to be followed by public etc, in a most possible concised manner illustrated in this presentation.
Corona virus disease-2019 (Covid-19 outbreak) epidemiology prevention and con...Arun Singh
This PPT is created and updated on 14 February 2020 and it is about the epidemiology of Corona Virus Disease-19, Its preventive measures were also given, useful for department of Community Medicine
There's a lot of information circulating about COVID-19, the disease caused by the new coronavirus, so it’s important to know what’s true and what’s not.
COVID-19
ALSO USEFUL FOR NEET, CET, JIPMER, AIIMS, OTHER MEDICAL ENTRANCES.
WATCH THE FULL VIDEO ON YOUTUBE:
https://youtu.be/1NQQvLH3xo0
SUBSCRIBE ON YOUTUBE !!
SUB-TOPICS INCLUDED ARE:
Introduction
Structure of SARS-CoV-2
Types of SARS-CoV-2
Transmission of SARS-CoV-2
Viability of the virus
Symptoms of COVID- 19
Diagnosis
Treatment
FOLLOW ON INSTAGRAM:
@stud_e_
https://www.instagram.com/stud_e_/
COVID-19 I Coronavirus Disease I Harshit JadavHarshit Jadav
This presentation highlights all the basic information regarding the current pandemic COVID-19.
This presentation includes an introduction, recent stats, the structure of coronavirus, pathogenesis of coronavirus, diagnosis, treatment and preventive measures of COVID-19
Coronaviruses are a large family of respiratory viruses that includes COVID-19MOHAhmed18
Coronaviruses are a large family of respiratory viruses that includes COVID-19, Middle East Respiratory Syndrome (MERS), and Severe Acute Respiratory Syndrome (SARS). Coronaviruses cause diseases in animals and humans. They often circulate among camels, cats, and bats, and can sometimes evolve and infect people.
Covid-19 is an infectious disease caused by SARS-CoV-2. mechsnism, pathogenesis and causes, transmission,symptoms and therapeutic strategies
Published by karuna raghuwanshi,M.pharma II semester (pharmaceutics),Pharmacy department.
Severe acute respiratory syndrome coronavirus 2, previously known by the provisional name 2019 novel coronavirus, is a positive-sense single-stranded RNA virus.
Coronavirus is the largest known RNA virus responsible for a range of respiratory illnesses in man. 7 Known coronaviruses have been identified with 4 causing mild infections and 3 severe diseases. The severe diseases are SARS, MERS and COVID-19
There is presently an ongoing epidemic of the disease in China which has gradually spread across the continent.
Covid 19--EMERGING AND FUTURE CHALLENGES FOR DENTAL SURGEONSOUMENDU KARAK
CORONAVIRUS (COVID-19)-EMERGING AND FUTURE CHALLENGES FOR DENTAL SURGEON.THE SLIDE DESCRIBE BRIEFLY ABOUT VIRUS,ITS CLINICAL MANIFESTATION,FATALITY RATE, MANAGMENT AND HOW WE OVERCOME FROM PRESENT SITUATION.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
Covid19 deepababin
1. COVID-19
This course provides a general introduction and awareness to
COVID-19 and is intended for public health professionals and
medical and paramedical students in developing countries.
Dr.Deepa Babin
Associate professor, Microbiology,SRMCRC,TVM
2.
3. Coronaviruses
• Large family of viruses that are known to cause
illness ranging from the common cold to more
severe diseases such as Severe Acute
Respiratory Syndrome (SARS-China 2003)and
Middle East Respiratory Syndrome (MERS –Saudi
Arabia 2012)
Middle East Respiratory Syndrome (MERS –Saudi
Arabia 2012)
• A novel coronavirus (COVID-19) was identified in
2019 in Wuhan, China with an outbreak of
respiratory illness
• A new coronavirus that has not been previously
identified in humans
4. What are Corona viruses?
• Cause of significant
percentage of all common
colds in human adults.
• Ccolds in humans primarily in
the winter and early springthe winter and early spring
season.
• Primarily infect the upper
respiratory and
gastrointestinal tract of
mammals and birds.
5. Classification
• Coronaviruses (CoVs) (order Nidovirales,
family Coronaviridae, subfamily Coronavirinae)
are enveloped viruses with a positive sense,
single-stranded RNA genome.
• With genome sizes ranging from 26 to 32• With genome sizes ranging from 26 to 32
kilobases (kb) in length, CoVs have the largest
genomes for RNA viruses.
• Based on genetic and antigenic criteria, CoVs
have been organised into three groups: α-CoVs,
β-CoVs, and γ-CoVs
6. Coronaviral genome
• Coronaviral genome encodes four major structural
proteins: the spike (S) protein, nucleocapsid (N)
protein, membrane (M) protein, and the envelope (E)
protein, all of which are required to produce a
structurally complete viral particlestructurally complete viral particle
• HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-
HKU1, are mild and self-limiting, SARS-CoV and MERS-
CoV cause severe infections that lead to high
mortality rates
• And the latest COVID-19 cause pandemic associated
severe respiratory conditions
8. COVID 19 STRUCTURE
• The CoV envelope (E) protein
is a small, integral membrane
protein involved in several
aspects of the virus’ life cycle,
such as assembly, budding,
envelope formation, and
pathogenesis.
• Name derived from the
Latin corona, meaning crown.
• Viral envelope under electron
microscopy appears crown-like
due to small bulbar
projections formed by the viral
spike (S) peplomers.
9. Naming of New Virus
• Disease -coronavirus disease- (COVID-
19)
• Virus-
Severe acute respiratory syndrome
coronavirus 2
(SARS-CoV-2)(SARS-CoV-2)
• Origin is uncertain although bats and
pangolins currently implicated.
– The preliminary genetic analysis appears
to find a great similarity to bat SARS-like
coronavirus (genus Betacoronavirus,
subgenus Sarbecovirus.
• Appears to be spread more easily
than SARS or MERS
10. Epidemiology
• Most commonly occurring in winter and
early spring.
– Incubation period -Mean of 6 days, range
2-12.
– For people quarantined, 14d observation
recommended to exclude infection,
though 24d asymptomatic time from
exposure described.exposure described.
– Viral shedding occurs following recovery,
but unclear what role this plays in
transmission.
– Children and intrafamilial spread appear
to be a growing means of transmission..
• Shedding may occur longer or also
occur in asymptomatic individuals.
11. Symptoms
– Fever (83-98%)
– Cough (46-82%, usually
dry)
– Shortness of breath at
onset (31%)
– Myalgia or fatigue (11-
44%)
– Less common– Less common
symptoms:
• Pharyngitis
• Headache
• Productive cough
• GI symptoms
– Have been described as a
presenting symptom
• Hemoptysis
12. Emergency warning signs
• If you develop emergency warning signs for COVID-19 get
medical attention immediately.
• Emergency warning signs include*:
• Trouble breathing
• Persistent pain or pressure in the chest
• New confusion or inability to arouse• New confusion or inability to arouse
• Bluish lips or face
• Fever may not be present in some patients, such as those
who are very young, elderly, immunosuppressed, or
taking certain medications.
• Clinical judgement should be used to guide testing of
patients in such situations.
13. Who are at risk?
• Children, Older adults,
Pregnancy and people
who have severe
underlying medical
conditions like heart or
lung disease or diabetes
conditions like heart or
lung disease or diabetes
seem to be at higher risk
for developing more
serious complications
from COVID-19 illness.
14. Who should be tested?
• Not everyone needs to be tested for COVID-
19.
• Most people have mild illness and are able to
recover at home or even asymptomatic
• There is no treatment specifically approved
for this virus.
• Testing results may be helpful to inform
decision-making about who you come indecision-making about who you come in
contact with.
• Decisions about testing are at the discretion
of state and local health departments and/or
individual clinicians.
• Clinicians should work with their state and
local health departments to coordinate
testing through public health laboratories, or
work with clinical laboratories.
15.
16.
17. •Confirmed cases•Confirmed cases •Confirmed
deaths
•Confirmed
deaths
• Countries,
areas or
• Countries,
areas or
TODAY 31 March 2020, 03:17 GMT+5:30
Coronavirus disease (COVID-19)
697,244
deathsdeaths
33,257
areas or
territories
areas or
territories
204
27. Where should nasopharyngeal swabs be performed
on a known or suspected COVID-19 patient, and with
what PPE?
• The collection of nasopharyngeal (NP) swabs
from patients with known or suspected COVID-
19 can be performed in a regular examination
room with the door closed.
• Use of an airborne infection isolation room for
nasopharyngeal specimen collection is not
required.required.
• Health care provider(HCP) in the room should
wear an N95 or higher-level respirator (or
facemask if a respirator is not available), eye
protection, gloves, and a gown.
• If respirators are not readily available, they
should be prioritized for other procedures at
higher risk for producing infectious aerosols
(e.g., intubation), instead of for collecting NP
swabs.
28. Specimen Type and Priority•
Nasopharyngeal specimen is the
preferred choice for swab-based
SARS-CoV-2 testing.
The following are acceptable
alternatives:
An oropharyngeal (OP) specimen,
A nasal mid-turbinate (NMT) swab
An anterior nares specimen
For patients who develop a
productive cough, sputum
When it is clinically indicated (e.g.,
those receiving invasive
mechanical ventilation), a lower
Maintain proper infection
control when collectingproductive cough, sputum
should be collected and tested
for SARS-CoV-2. The induction
of sputum is not
recommended.
mechanical ventilation), a lower
respiratory tract aspirate or
bronchoalveolar lavage sample
should be collected and tested as a
lower respiratory tract specimen.
control when collecting
specimens.
Biosafety for handling and
processing specimens from
suspected case patients.
For NS, a single
both nares.
For NS, a single
polyester swab with a
plastic shaft should
be used to sample
both nares.
NS or NMT swabs should be
placed in a transport tube
containing either viral
transport medium, Amies
transport medium, or sterile
saline.
If both NP and OP
swabs both are
collected, they should
be combined in a single
tube to maximize test
sensitivity
29. Upper respiratory tract
Nasopharyngeal swab (NP) /oropharyngeal swab
(OP)
• Use only synthetic fiber swabs with plastic shafts.
• Do not use calcium alginate swabs or swabs with wooden shafts, as they
may contain substances that inactivate some viruses and inhibit PCR
testing.
• Place swabs immediately into sterile tubes containing 2-3 ml of viral
transport media.
• If both swabs are used, NP and OP specimens should be combined at
collection into a single vial. OP swabs remain an acceptable specimen
type.
collection into a single vial. OP swabs remain an acceptable specimen
type.
• Nasopharyngeal swab: Insert a swab into nostril parallel to the palate.
• Swab should reach depth equal to distance from nostrils to outer
opening of the ear. Leave swab in place for several seconds to absorb
secretions. Slowly remove swab while rotating it.
Oropharyngeal swab (e.g., throat swab): Swab the posterior pharynx,
avoiding the tongue.
• Nasopharyngeal wash/aspirate or nasal aspirate
• Collect 2-3 mL into a sterile, leak-proof, screw-cap sputum collection cup
or sterile dry container.
30. Storage
• Store specimens at 2-8°C for up to 72 hours
after collection.
• If a delay in testing or shipping is expected,
store specimens at -70°C or below.store specimens at -70°C or below.
31. Laboratory testing
• CDC 2019-nCoV Real-Time RT-PCR
Diagnostic Panel contains the
following:
• 2019-nCoV_N1, 2019-nCoV_N2 and
2019-nCoV_N3 primers and probes
that target the nucleocapsid (N)
gene and are designed for both
universal detection of SARS-like
coronavirus as well as specific
universal detection of SARS-like
coronavirus as well as specific
detection of the 2019-nCoV;
• RP primers and probes that target
the Human RNase P gene
• nCoVPC, the 2019-nCoV positive
control used in the assay.
32. Laboratory Mannual
Use either a certified
Class II Biological Safety
Cabinet (BSC) or
additional precautions
to provide a barrier
between the specimen
and personnel.
Personal protective
equipment (PPE), such as a
surgical mask or face shield,
or other physical barriers,
like a splash shield
centrifuge safety cups; and
sealed centrifuge rotors to
reduce the risk of exposure
to laboratory personnel.
Decontaminate work surfaces and
equipment with appropriate disinfectants.
Use disinfectants with label claims to be
effective against SARS-CoV-2external icon.
Follow manufacturer’s recommendations for
use, such as dilution, contact time, and safe
handling.
Laboratory Waste Management
Handle laboratory waste from
testing suspected or confirmed
COVID-19 patient specimens as all
other biohazardous waste in the
laboratory.
Currently, there is no evidence to
suggest that this laboratory waste
needs any additional packaging or
disinfection procedures
Specimen Packing and Shipping
Pack and ship suspected and
confirmed SARS-CoV-2 patient
specimens, cultures, or isolates
as Biological Substance,
Category B,
Personnel must be trained to
pack and ship according to the
regulations and in a manner
that corresponds to their
function-specific
responsibilities.
33. Treatment
• There is no specific antiviral treatment
recommended for COVID-19, and no vaccine is
currently available.
• The treatment is symptomatic, and oxygen
therapy represents the major treatmenttherapy represents the major treatment
intervention for patients with severe infection.
• Mechanical ventilation may be necessary in
cases of respiratory failure refractory to oxygen
therapy, whereas hemodynamic support is
essential for managing septic shock.
34. PREVENTION
• The best way to prevent illness is to
avoid being exposed to this virus.
• The virus is thought to spread
mainly from person-to-person.
• Between people who are in close
contact with one another (within
about 6 feet).about 6 feet).
• Through respiratory droplets
produced when an infected person
coughs or sneezes.
• These droplets can land in the
mouths or noses of people who are
nearby or possibly be inhaled into
the lungs.
35. PREVENTION
• Clean your hands often
• Wash your hands often with soap and
water for at least 20 seconds especially
after you have been in a public place, or
after blowing your nose, coughing, or
sneezing.
• If soap and water are not readily• If soap and water are not readily
available, use a hand sanitizer that
contains at least 60% alcohol.
• Cover all surfaces of your hands and rub
them together until they feel dry.
• Avoid touching your eyes, nose, and
mouth with unwashed hands.
• Fumigation using sodium hypochloride
36.
37. Drugs currently under investigation
• Remdesivir (Gilead; used to treat Ebola)
– Currently under study in a trial in Wuhan and U.S.; activity is seen in
vitro with SARS-2-CoV, MERS-CoV (also including MERS-CoV primate
studies)
– Likely the most promising drug
– Drug has been used in the U.S. under compassionate use; however,
unclear how long this will last
• Chloroquine (or hydroxychloroquine; HCQ) has been reported• Chloroquine (or hydroxychloroquine; HCQ) has been reported
to have some efficacy in vivo and in limited, very low-quality
evidence for COVID-19 pneumonia, the mechanism may be by
interfering with cellular acidification in the phagolysosome.
• ASC09/oseltamivir, ritonavir/oseltamivir, oseltamivir
• Azvudine
• All under trial with limited possibilities ..............
39. Take everyday preventive steps
• Wash your hands frequently
• Avoid touching your eyes, nose, and mouth.
• Stay home when you are sick.
• Cover your cough or sneeze with a tissue, then• Cover your cough or sneeze with a tissue, then
throw the tissue in the trash.
• Clean and disinfect frequently touched objects
and surfaces
• Social Distancing
40.
41. Resources
• WHO has provided recommendations to reduce risk of
transmission from animals to humans
• WHO has published an updated advice for international traffic
in relation to the outbreak of the novel coronavirus 2019-nCoV.
• WHO has activated the R&D blueprint to accelerate
diagnostics, vaccines, and therapeutics.diagnostics, vaccines, and therapeutics.
• OpenWHO is an interactive, web-based, knowledge-transfer
platform offering online courses to improve the response to
health emergencies.
• COVID-19 courses can be found here and courses in additional
national languages here.
• CDC Laboratory Biosafety Frequently Asked Questions
• EPA List N: Disinfectants for Use Against SARS-CoV-2external
icon
• Saf-T-Pak Packaging Checklist, see Category Bpdf icon